Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV0AH8)

Drug Name

TCN-P Drug Info

Synonyms

TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

Cross-matching ID

PubChem CID: 43860
CAS Number: CAS 61966-08-3
TTD Drug ID: DMV0AH8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting RAC-gamma serine/threonine-protein kinase (AKT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[3]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[4]
MK-2206	DMT1OZ6	Rectal adenocarcinoma	2B92	Phase 2	[5]
GSK2141795	DMSHE70	Colorectal cancer	2B91.Z	Phase 2	[6]
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LYS-6KAKT1	DMLXGAI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
LY2780301	DM93AJW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
XL418	DME0F5W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
SR13668	DMO5760	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
GSK690693	DMRBVHE	Haematological malignancy	2B33.Y	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
RAC-gamma serine/threonine-protein kinase (AKT3)	TTAZ05C	AKT3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00363454) Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer. U.S. National Institutes of Health.
2	Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9.
3	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
6	Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	DOI: 10.1016/S1359-6349(10)71767-5
9	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
10	Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
11	Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53.
12	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74.